6 March 2020 projects
Audentes Therapeutics, a genetic medicines company, is planning to build a gene therapy manufacturing facility in Sanford, North Carolina, US.
4 March 2020 Analysis
In 2019, the opioid crisis in the US reached its peak. It dominated the news and legislative agenda and two pharma companies declared bankruptcy as a result of multiple legal...
28 February 2020 News
Biogen and Sangamo Therapeutics have signed a global licensing agreement for the development of drugs to treat neurological diseases, including Alzheimer’s and Parkinson’s diseases.
25 February 2020 Comment
Epilepsy is a common neurological condition where abnormal activity in the brain leads to seizures. This condition is usually diagnosed after a person has experienced two or more unprovoked seizures....
11 February 2020 Company News
Eli Lilly has announced its drug solanezumab failed to meet its primary endpoint in the Phase II/III Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) study.
5 February 2020 Analysis
Despite halting development after disappointing trial findings in March, Biogen now plans to submit Alzheimer’s candidate aducanumab for FDA approval, after new analysis showed the drug just might work. Natalie...
20 December 2019 News
The European Commission (EC) has approved Johnson & Johnson subsidiary Janssen’s Spravato (esketamine) nasal spray for treatment-resistant major depressive disorder.
9 December 2019 Research Reports
Glioblastoma multiforme (GBM), also known as Grade IV astrocytoma, is the most aggressive form of brain cancer and has one of the highest unmet needs in the oncology market. The...